Stop by our booth #40 for a deep dive into the future of oncology diagnostics!
September 3 – 6, 2024
Boston, MA
world-cdx.com
Together for a better healthcare journey
We are fully committed to providing unwavering support to our biopharma clients at every stage of the clinical trial process. Our aim is to deliver seamless end-to-end solutions without any compromises or unnecessary complexities. Our extensive portfolio includes a wide range of cfDNA and cfRNA NGS services, all backed by an exceptional project management team that sets us apart.
Expert presentation:
Join us for an insightful presentation by our expert on the use of cfHPV-DNA as a biomarker for HPV-associated OPSCC!
The Rise of cfHPV-DNA as a Biomarker for HPV-Associated OPSCC
Date: September 5, 2024; Day 2 TRACK B Clinical Biomarker Development
Time: 3:10 pm
Presented by: Nishant Agrawal, MD, Professor of Surgery, Co-Director, Head and Neck Surgical Oncology Chief of Otolaryngology – Head and Neck Surgery, University of Chicago
Synopsis:
- Assess patients’ trial eligibility, by determining patients’ HPV status and subtype with a simple blood draw.
- Gain real-time insights into treatment response, by assessing dynamic changes in cfHPV-DNA quantitatively over the course of treatment.
- Detect recurrent disease — including distant recurrence — early, with detection that precedes the current standard of care.